

VNS THERAPY™ MILESTONES

2007	July 16	10-year anniversary of FDA Approval of VNS Therapy for refractory epilepsy. To date, more than 45,000 patients have been treated worldwide with VNS Therapy for both epilepsy and depression, representing more than 150,000 patient years of treatment experience with VNS Therapy.
	July 16	Cyberonics announces that the company has received FDA approval to market the VNS Therapy Demipulse and Demipulse Duo Generators. The new model is 43 percent smaller in volume than the Model 102 and provides added features for patients and their physicians, including continuous projection of time to end of service, improved diagnostics and faster communication with a programming system.
	February 1	Published research in <i>Epilepsy & Behavior</i> shows that the incidences of hospital visits and hospitalizations are significantly decreased among a VNS Therapy epilepsy patient population.
2005	July 15	The FDA approves Cyberonics' VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more antidepressant treatments.
	March 23	New research published in the <i>European Journal of Neurology</i> recommends other therapeutic options for those with epilepsy who have failed two or more antiepileptic drug treatment regimens.
2004	December 2	Following a comprehensive audit of its facilities, Cyberonics receives renewal approval of CE Mark to market the VNS Therapy System in Europe and Canada.
	September 1	Study results published in <i>Epilepsia</i> indicate that seizure control improves in patients with epilepsy when VNS Therapy increases blood flow in the thalamic areas of the brain.
2003	August 18	Cyberonics announces FDA approval to market the VNS Therapy Model 102R Generator for the treatment of refractory epilepsy. The Model 102R Generator is a dual connector version of the Model 102 Generator for use as a replacement for Model 100 and 101 Generators. Like the Model 102 Generator, the Model 102R is slimmer, lighter and has less volume than its predecessor.
	April 2	The FDA approves the addition of an animal study, which revealed no evidence of impaired fertility or harm to the fetus due to VNS Therapy, into the VNS Therapy labeling.
2002	June 24	The new Pulse Model 102 VNS Therapy Product Family launches in the U.S. four months ahead of schedule. The new Model 102 Generator is 33% thinner, 34% lighter and has 43% less volume than its predecessor, the Model 101 Generator. The Epilepsy Foundation says the new VNS Therapy model is more patient friendly.
	April 18	A study published in <i>Neurology</i> indicates VNS Therapy is more effective in patients with epilepsy when used earlier in the course of condition or treatment.
	April 18	A study published in <i>Neurology</i> showed that reducing antiepileptic

Сурегопіся Ергрков-11-2000



-		
		drugs in patients using VNS Therapy does not impair effectiveness in controlling seizures.
	Ianuary 1	A study published in <i>Enilepsia</i> shows that as separate treatments
	bulldur y 1	enilensy surgery or VNS Therapy more effectively control seizures
		when compared with continued treatment with antienilentic drugs
		and enilency related direct medical costs decreased in surgically
		treated and VNS Therepy patient groups
2001	Annil 11	Study results published in <i>Neurolean</i> show that UNS Thereau
2001	April 11	study results published in <i>Neurology</i> show that VNS Therapy
		effectively reduces the need for antiepileptic drugs in patients with
		retractory epilepsy.
	March 26	Study results published in <i>Epilepsy & Behavior</i> show that VNS
		Therapy may positively impact quality of life in patients with
		epilepsy.
2000	December	A study published in <i>Neurology</i> shows that VNS Therapy improves
		the quality life for patients with epilepsy aged 50 and older.
	October 12	A study published in <i>Epilepsia</i> shows that VNS Therapy is an
		effective long-term treatment for patients with refractory epilepsy.
	August 25	Cyberonics launches VNS Therapy Access Program, a \$5 million
	U	initiative to make VNS Therapy accessible to individuals without
		medical insurance coverage.
	June 20	Research published in <i>Enilepsia</i> shows mortality and SUDEP
	June 20	(sudden unexplained death in enilensy) rates dron significantly
		among patients with epilepsy treated with VNS Therapy
	Lonvom: 21	Cuberonics announces the next conception Model 101 VNS Thereasy.
	January 51	Cyberonics announces the next generation Model 101 VINS Therapy
		System, which is 22 percent thinner, 31 percent lighter and has up to
1000	NT 1 1	a 91 percent longer battery life than its predecessor.
1999	November 1	Results published in <i>Neurology</i> from an open-label, long-term
		efficacy study show that VNS Therapy is effective in reducing
		seizures.
	September 13	The American Academy of Neurology taskforce assessment
		published in <i>Nature Neuroscience</i> indicates VNS Therapy safe and
		effective in epilepsy based on a preponderance of Type I data (one
		or more controlled studies).
	June 28	Study results presented by researchers at Cornell University, New
		York Presbyterian Hospital, show that VNS Therapy significantly
		improves mood in patients with treatment-resistant epilepsy.
	January 1	Study results published in <i>Nature Neuroscience</i> show that VNS
	2	Therapy enhances memory in humans.
1998	April 1	The Centers for Medicare and Medicaid Services (CMS) (formerly
	r	known as the Health Care Finance Administration: HCFA) provides
		national Medicare coverage for VNS Therapy in epilepsy
1997	July 16	The EDA approves the VNS Therapy System (formerly known as
1))/	July 10	the NCP NeuroCybernetic Prosthesis System (formerly known as
		the INCF ^o NeuroCybernetic Frostnesis System) as an adjunctive
		ueatment for adults and children over 12 years of age with partial
1000		onset seizures refractory to drugs.
1988	November 16	First numan implant of the VNS Therapy System by Dr. J. Kiffin
		Penry (neurologist) and William Bell (neurosurgeon) at Wake Forest
		Bowman Gray Medical School.

Сурегопіся Ергрков-11-2000